| Xu HB[15] |
Eur J Clin Pharmacol (2015) |
Capecitabine+ oxaliplatin (XELOX) vs. 5-fluorouracil/ leucovorin+ oxaliplatin (FOLFOXs) |
NA. |
Overall RR: statistically similar |
NA. |
Clinical benefit rate: statistically similar. Nausea, stomatitis, diarrhea and alopecia: lower in capecitabine regimen. Hand-foot syndrome: higher in capecitabine based regimen. |
Owing to limited data and potential bias of the included studies, further rigorously controlled trials are required. |
| Ma Y[40] |
J Clin Pharm Ther (2012) |
Capecitabine-based vs.5-FU-based therapy. |
Favor capecitabine-based chemotherapy |
Overall RR: favor capecitabine-based chemotherapy |
NA. |
Grade 3 or 4 leukopenia, stomatitis and nausea and vomiting, hand-foot syndrome: lower in capecitabine-based regimens; Haematological toxicity: statistically similar |
Capecitabine based chemotherapy strategies showed prolonged OS and enhanced overall RR.AGC. Asian patients also showed less grade 3/4 gastrointestinal toxicity with the capecitabine based regimens compared with Caucascian patients. |
| Wagner AD[51] |
Cochrane Database Syst Rev (2010) |
(Include regimens containing oral 5-FU prodrugs vs. intravenous fluoropyrimidines). |
Statistically similar |
Objective RR: favor capecitabine- containing regimen |
PFS: statistically similar. |
Treatment related death, treatment discontinuation due to toxicity: statistically similar. |
Gastric cancer patients with adequate renal function and compliance should be treated with capecitabine instead of 5-FU. |
